<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610545</url>
  </required_header>
  <id_info>
    <org_study_id>FCM-UNICAMP - 620/2006</org_study_id>
    <secondary_id>0492.0.146.000-06</secondary_id>
    <nct_id>NCT00610545</nct_id>
  </id_info>
  <brief_title>Atorvastatin in Perioperative Vascular Surgery - Pilot Study</brief_title>
  <acronym>APVS</acronym>
  <official_title>Atorvastatin 80mg Versus Atorvastatin 20mg in Perioperative Vascular Surgery to Evaluate Cardiovascular Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine if the use of atorvastatin (Lipitor), a member of the HMG
      coA reductase inhibitor class of drugs referred to as statins, will reduce cardiovascular
      outcomes ( mortality - myocardial infarction - stroke ) when given in high doses in
      comparative standard doses in the perioperative period of major vascular surgery.

      Abdominal aortic aneurysm , Carotid endarterectomy , Revascularization of lower limbs
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality ; myocardial infarction ; stroke</measure>
    <time_frame>within 90 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline to the surgery of treatment for LDL-C, HDL-C, TC, and TG for subjects</measure>
    <time_frame>within 24h before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline to the surgery of treatment for hs-CRP</measure>
    <time_frame>within 24h before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of atorvastatin through laboratory assessment</measure>
    <time_frame>within 24h before surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vascular Surgery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vascular surgery (abdominal aortic aneurysm , carotid endarterectomy , limbs
             revascularization)

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patient with sensitivity to atorvastatin

          -  Patient has elevations in certain laboratory values (CK, AST, ALT)

          -  Known history of active hepatic disease or known hepatic insufficiency

          -  Patients participating in another clinical trial

          -  Prior statin therapy to include: &gt;10 mg of atorvastatin (Lipitor) or &gt;20 mg of other
             HMG-CoA Reductase Inhibitors (statins) or use rosuvastatin

          -  Serious infectious disease after surgery

          -  Known history of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>OTAVIO COELHO, PhD</last_name>
    <role>Study Director</role>
    <affiliation>STATE UNIVERSITY CAMPINAS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RAITANY C ALMEIDA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>STATE UNIVERSITY CAMPINAS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinics Hospital - State University Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SÃ£o Paulo</state>
        <zip>13083970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2008</study_first_posted>
  <last_update_submitted>February 13, 2009</last_update_submitted>
  <last_update_submitted_qc>February 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>RAITANY COSTA DE ALMEIDA</name_title>
    <organization>STATE UNIVERSITY OF CAMPINAS</organization>
  </responsible_party>
  <keyword>ATORVASTATIN</keyword>
  <keyword>VASCULAR SURGERY</keyword>
  <keyword>CARDIOVASCULAR OUTCOMES</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

